Whether people with HIV had hepatitis or not didn't change the relationship between losing belly fat and improving liver enzymes.

Scientific Claim

The association between visceral adipose tissue reduction and improved liver enzymes in HIV-infected patients was not modified by viral hepatitis status.

Original Statement

“The relationship between responder status and change in transaminases among tesamorelin-treated patients was not modified by viral hepatitis status. Thus, VAT responders with and without viral hepatitis had comparable declines in liver enzymes.”

From study:Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

association

Can only show association/correlation

Assessment Explanation

The claim correctly describes the lack of interaction without causal language. The study design supports this assessment of effect modification.

Evidence from Studies

Supporting (1)

Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV

Randomized Controlled Trial

Human

2017 Oct 23

Contradicting (0)

No contradicting evidence found

Source Study

Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV

Score: 62

DOI: 10.1097/QAD.0000000000001614

Similar Assertions

Whether HIV patients had hepatitis or not didn't change the benefit of visceral fat loss on liver enzymes when taking tesamorelin.

92%

Whether HIV patients had hepatitis or not didn't change the link between losing visceral fat and improving liver enzyme levels.

92%

Whether HIV patients had hepatitis or not didn't change the link between losing visceral fat and improving liver enzymes.

85%

For HIV patients with belly fat and high liver enzymes, losing visceral fat improved liver enzymes whether they had hepatitis or not.

83%

In people with HIV and belly fat, the amount of visceral fat didn't correlate with liver enzyme AST levels when other factors like sex and hepatitis were considered.

82%